What is Bicara Therapeutics's debt-to-equity?

Bicara Therapeutics (BCAX) reported debt-to-equity of 0× in Q1 2026.

How has Bicara Therapeutics's debt-to-equity changed year-over-year?

Bicara Therapeutics's debt-to-equity increased by 115.4% year-over-year, from 0× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Bicara Therapeutics BCAX Debt-to-equity

Debt-to-equity at other companies

Eli LillyLLY

1.4×-1.1×

AmgenAMGN

6.2×-3.0×

ArriVent BioPharma, Inc.AVBP

0×0.0×

ImmunomeIMNM

0×0.0×

Arcus BiosciencesRCUS

0.2×+0.1×

Syndax PharmaceuticalsSNDX

8.4×+6.9×

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

total debt/total stockholders equity=0×

Based on the most recent quarter.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's debt-to-equity?: Bicara Therapeutics (BCAX) reported debt-to-equity of 0× in Q1 2026.
How has Bicara Therapeutics's debt-to-equity changed year-over-year?: Bicara Therapeutics's debt-to-equity increased by 115.4% year-over-year, from 0× to 0×.
What does debt-to-equity mean?: Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.